Asia Pacific Cell And Gene Therapy Cdmo Market Size & Outlook
Asia Pacific cell and gene therapy cdmo market, 2018-2030 (US$M)
Related Markets
Asia Pacific cell and gene therapy cdmo market highlights
- The Asia Pacific cell and gene therapy cdmo market generated a revenue of USD 1,872.4 million in 2023.
- The market is expected to grow at a CAGR of 28.7% from 2024 to 2030.
- In terms of segment, pre-clinical was the largest revenue generating by phase in 2023.
- Pre-clinical is the most lucrative by phase segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 1,872.4 million |
| Market revenue in 2030 | USD 10,925.1 million |
| Growth rate | 28.7% (CAGR from 2023 to 2030) |
| Largest segment | Pre-clinical |
| Fastest growing segment | Pre-clinical |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pre-clinical, Clinical |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 37.6% of the global cell and gene therapy cdmo market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 10,925.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy CDMO Market Scope
Cell And Gene Therapy CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific cell and gene therapy cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.18% in 2023. Horizon Databook has segmented the Asia Pacific cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific held the revenue share of 37.55% in the global market in 2023. This growth can be attributed to various factors, such as improved social insurance schemes and constantly improving economic conditions in the region, which allow patients to pay out-of-pocket pharmaceutical costs.
In recent years, countries such as Singapore, China, and India are considered to be major players in the pharmaceutical industry due to their expanding manufacturing capabilities. In addition, the manufacturing of pharmaceutical products has been outsourced to Asian countries in the past decade, including India & China.
Furthermore, the availability of a large number of potential study subjects has driven several pharmaceutical companies, such as Eli-Lilly and GlaxoSmithKline, to conduct clinical studies in Asian countries, such as India.
Reasons to subscribe to Asia Pacific cell and gene therapy cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific cell and gene therapy cdmo market databook
-
Our clientele includes a mix of cell and gene therapy cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific cell and gene therapy cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific cell and gene therapy cdmo market size, by country, 2018-2030 (US$M)
Asia Pacific Cell And Gene Therapy CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
